Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2023-12-12 00:00:00 ET · period of report 2023-12-08 · accession 0001968202-23-000052 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-12-12 | 2023-12-08+ | REGN | LAROSA JOSEPH J | EVP GC, Secret | F - Tax | $843.92 | -1,521 | 30.0K | -5% | -$1.28M |
| D | 2023-12-12 | 2023-12-08 | REGN | LAROSA JOSEPH J | EVP GC, Secret | A - Grant | $0.00 | +2,133 | 30.7K | +7% | $0 |
| D | 2023-12-12 | 2023-12-08 | REGN | LAROSA JOSEPH J | EVP GC, Secret | A - Grant | $0.00 | +7,649 | 7,649 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-08 | F | D | 852 | $843.79 | 28,572 | D | — | — | |
| 2 | Common | Common Stock | 2023-12-08 | A | A | 2,133 | $0.00 | 30,705 | D | — | — | |
| 3 | Common | Common Stock | 2023-12-11 | F | D | 669 | $844.09 | 30,036 | D | — | — | |
| 4 | Derivative | Non-Qualified Stock Option (right to buy) | 2023-12-08 | A | A | 7,649 | $0.00 | 7,649 | D | $843.79 · — to 2033-12-08 | 7,649 Common Stock | (F2) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |